Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Intellia Therapeutics
Modality
UNKNOWN
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06672237CT.gov A Phase 3 Study of NTLA-2001 in ATTRv-PN | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Indicative
Detailed axis rationale is planned and will be published soon.
Same indication · Familial Amyloid Neuropathy
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Nexiguran Ziclumeran (this asset) | Intellia Therapeutics | P3 | B · 60 |
| Tafamidis | Qilu Pharmaceutical Co., Ltd. | P4 | A |
| Inotersen | Akcea Therapeutics | P4 | BB |
| Revusiran | Alnylam Pharmaceuticals | P3 | BB |
| Patisiran | Alnylam Pharmaceuticals | P3 | BB |
| (1,1'-BIPHENYL)-3-CARBOXYLIC ACID, 2',4'-DIFLUORO-4-HYDROXY- | Boston University | P2/3 | B |
| Acoramidis | Eidos Therapeutics, a BridgeBio company | P3 | B |
| Aln-Ttrsc02 | Alnylam Pharmaceuticals | P3 | B |
| Nucresiran | Alnylam Pharmaceuticals | P3 | B |
+3 more in the Familial Amyloid Neuropathy cohort
Other indications for Nexiguran Ziclumeran
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Neurodegeneration With Brain Iron Accumulation | — | P3 | B · 60 |
| Inherited Neurodegenerative Disorder | — | P3 | B · 60 |
| Neuromuscular Disease | — | P3 | B · 60 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Nexiguran Ziclumeran in Familial Amyloid Neuropathy. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/nexiguran-ziclumeran-familial-amyloid-neuropathy
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →